Abstract
Altered dopamine receptor labelling has been demonstrated in presymptomatic and symptomatic Huntington’s disease (HD) gene carriers, indicating that alterations in dopaminergic signalling are an early event in HD. We have previously described early alterations in synaptic transmission and plasticity in both the cortex and hippocampus of the R6/1 mouse model of Huntington’s disease. Deficits in cortical synaptic plasticity were associated with altered dopaminergic signalling and could be reversed by D1- or D2-like dopamine receptor activation. In light of these findings we here investigated whether defects in dopamine signalling could also contribute to the marked alteration in hippocampal synaptic function. To this end we performed dopamine receptor labelling and pharmacology in the R6/1 hippocampus and report a marked, age-dependent elevation of hippocampal D1 and D2 receptor labelling in R6/1 hippocampal subfields. Yet, pharmacological inhibition or activation of D1- or D2-like receptors did not modify the aberrant synaptic plasticity observed in R6/1 mice. These findings demonstrate that global perturbations to dopamine receptor expression do occur in HD transgenic mice, similarly in HD gene carriers and patients. However, the direction of change and the lack of effect of dopaminergic pharmacological agents on synaptic function demonstrate that the perturbations are heterogeneous and region-specific, a finding that may explain the mixed results of dopamine therapy in HD.
Similar content being viewed by others
References
Amenta, F., Mignini, F., Ricci, A., Sabbatini, M., Tomassoni, D., & Tayebati, S. K. (2001). Age-related changes of dopamine receptors in the rat hippocampus: A light microscope autoradiography study. Mechanisms of Ageing and Development, 122(16), 2071–2083.
André, V. M., Cepeda, C., & Levine, M. S. (2010). Dopamine and glutamate in Huntington’s disease: A balancing act. CNS Neuroscience & Therapeutics, 16(3), 163–178.
Andrews, T. C., Weeks, R. A., Turjanski, N., Gunn, R. N., Watkins, L. H., Sahakian, B., et al. (1999). Huntington’s disease progression: PET and clinical observations. Brain, 122(12), 2353–2363.
Antonini, A., Leenders, K. L., & Eidelberg, D. (1998). [11C]Raclopride-PET studies of the Huntington’s disease rate of progression: Relevance of the trinucleotide repeat length. Annals of Neurology, 43(2), 253–255.
Ariano, M. A., Aronin, N., Difiglia, M., Tagle, D. A., Sibley, D. R., Leavitt, B. R., et al. (2002). Striatal neurochemical changes in transgenic models of Huntington’s disease. Journal of Neuroscience Research, 68(6), 716–729.
Bolivar, V. J., Manley, K., & Messer, A. (2004). Early exploratory behavior abnormalities in R6/1 Huntington’s disease transgenic mice. Brain Research, 1005(1–2), 29–35.
Brito, V., Giralt, A., Enriquez-Barreto, L., Puigdellívol, M., Suelves, N., Zamora-Moratalla, A., et al. (2014). Neurotrophin receptor p75(NTR) mediates Huntington’s disease-associated synaptic and memory dysfunction. The Journal of Clinical Investigation, 124(10), 4411–4428.
Cepeda, C., Murphy, K. P. S., Parent, M., & Levine, M. S. (2014). The role of dopamine in Huntington’s disease. Progress in Brain Research, 211, 235–254.
Chritin, M., Savasta, M., Mennicken, F., Bal, A., Abrous, D. N., Le Moal, M., et al. (1992). Intrastriatal dopamine-rich implants reverse the increase of dopamine D2 receptor mRNA levels caused by lesion of the nigrostriatal pathway: A quantitative in situ hybridization study. The European Journal of Neuroscience, 4(7), 663–672.
Colgin, L. L., Moser, E. I., & Moser, M.-B. (2008). Understanding memory through hippocampal remap**. Trends in Neurosciences, 31(9), 469–477.
Cummings, D. M., Milnerwood, A. J., Dallérac, G. M., Waights, V., Brown, J. Y., Vatsavayai, S. C., et al. (2006). Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington’s disease. Human Molecular Genetics, 15(19), 2856–2868.
Dallerac, G., Chever, O., & Rouach, N. (2013). How do astrocytes shape synaptic transmission? Insights from electrophysiology. Frontiers in Cellular Neuroscience, 7, 159.
Dallérac, G. M., Levasseur, G., Vatsavayai, S. C., Milnerwood, A. J., Cummings, D. M., Kraev, I., et al. (2015). Dysfunctional dopaminergic neurones in mouse models of Huntington’s disease: a role for SK3 channels. Neuro-Degenerative Diseases, 15(2), 93–108.
Dallérac, G. M., Vatsavayai, S. C., Cummings, D. M., Milnerwood, A. J., Peddie, C. J., Evans, K. A., et al. (2011). Impaired long-term potentiation in the prefrontal cortex of Huntington’s disease mouse models: rescue by D(1) dopamine receptor activation. Neurodegenerative Diseases, 8(4), 230–239.
Ginovart, N., Lundin, A., Farde, L., Halldin, C., Bäckman, L., Swahn, C. G., et al. (1997). PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington’s disease. Brain, 120(3), 503–514.
Glass, M., Dragunow, M., & Faull, R. L. M. L. (2000). The pattern of neurodegeneration in Huntington’s disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience, 97(3), 505–519.
González-Burgos, I., & Feria-Velasco, A. (2008). Serotonin/dopamine interaction in memory formation. Progress in Brain Research, 172, 603–623.
Hansen, N., & Manahan-Vaughan, D. (2014). Dopamine D1/D5 receptors mediate informational saliency that promotes persistent hippocampal long-term plasticity. Cerebral Cortex (New York, N.Y.: 1991), 24(4), 845–858.
Harper, P. (1996). Huntington’s disease. In W. B. Saunders (Ed.), Major problems of neurology (2nd ed.). Philadelphia, PA: WB Saunders.
Heng, M. Y., Tallaksen-Greene, S. J., Detloff, P. J., & Albin, R. L. (2007). Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington’s disease. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 27(34), 8989–8998.
Hodgson, J. G. G., Agopyan, N., Gutekunst, C.-A. A., Leavitt, B. R., LePiane, F., Singaraja, R., et al. (1999). A YAC mouse model for Huntington’s disease with full-length mutant Huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 23(1), 181–192.
Huang, Y.-Y. Y., Simpson, E., Kellendonk, C., & Kandel, E. R. (2004). Genetic evidence for the bidirectional modulation of synaptic plasticity in the prefrontal cortex by D1 receptors. Proceedings of the National Academy of Sciences of the United States of America, 101(9), 3236–3241.
Jay, T. M. (2003). Dopamine: A potential substrate for synaptic plasticity and memory mechanisms. Progress in Neurobiology, 69(6), 375–390.
Johnson, M. A., Rajan, V., Miller, C. E., & Wightman, R. M. (2006). Dopamine release is severely compromised in the R6/2 mouse model of Huntington’s disease. Journal of Neurochemistry, 97(3), 737–746.
Kelly, M. A., Rubinstein, M., Asa, S. L., Zhang, G., Saez, C., Bunzow, J. R., et al. (1997). Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron, 19(1), 103–113.
Koob, G. F., Stinus, L., & Le Moal, M. (1981). Hyperactivity and hypoactivity produced by lesions to the mesolimbic dopamine system. Behavioural Brain Research, 3(3), 341–359.
Korchounov, A., Meyer, M. F., & Krasnianski, M. (2010). Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation. Journal of Neural Transmission (Vienna, Austria: 1996), 117(12), 1359–1369.
Kung, V. W. S., Hassam, R., Morton, A. J., & Jones, S. (2007). Dopamine-dependent long term potentiation in the dorsal striatum is reduced in the R6/2 mouse model of Huntington’s disease. Neuroscience, 146(4), 1571–1580.
LaHoste, G. J., & Marshall, J. F. (1989). Non-additivity of D2 receptor proliferation induced by dopamine denervation and chronic selective antagonist administration: Evidence from quantitative autoradiography indicates a single mechanism of action. Brain Research, 502(2), 223–232.
Li, L., Murphy, T. H., Hayden, M. R., & Raymond, L. A. (2004). Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. Journal of Neurophysiology, 92(5), 2738–2746.
Lynch, G., Kramar, E. A., Rex, C. S., Jia, Y., Chappas, D., Gall, C. M., & Simmons, D. A. (2007). Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington’s disease. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 27(16), 4424–4434.
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87(3), 493–506.
Milner, A. J., Cummings, D. M., Spencer, J. P., & Murphy, K. P. S. J. (2004). Bi-directional plasticity and age-dependent long-term depression at mouse CA3-CA1 hippocampal synapses. Neuroscience Letters, 367(1), 1–5.
Milnerwood, A. J., Cummings, D. M., Dallerac, G. M., Brown, J. Y., Vatsavayai, S. C., Hirst, M. C., et al. (2006). Early development of aberrant synaptic plasticity in a mouse model of Huntington’s disease. Human Molecular Genetics, 15(10), 1690–1703.
Mochel, F., Durant, B., Durr, A., & Schiffmann, R. (2011). Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice. PLoS ONE, 6(3), e18336.
Murphy, K. P. S. J., Carter, R. J., Lione, L. A., Mangiarini, L., Mahal, A., Bates, G. P., et al. (2000). Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington’s disease mutation. Journal of Neuroscience, 20(13), 5115–5123.
Ortiz, A. N., Kurth, B. J., Osterhaus, G. L., & Johnson, Ma. (2011). Impaired dopamine release and uptake in R6/1 Huntington’s disease model mice. Neuroscience Letters, 492(1), 11–14.
Plotkin, J. L., Day, M., Peterson, J. D., **e, Z., Kress, G. J., Rafalovich, I., et al. (2014). Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington’s disease. Neuron, 83(1), 178–188.
Savasta, M., Mennicken, F., Chritin, M., Abrous, D. N., Feuerstein, C., Le Moal, M., & Herman, J. P. (1992). Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study. Neuroscience, 46(3), 729–738.
Shohamy, D., & Adcock, R. A. (2010). Dopamine and adaptive memory. Trends in Cognitive Sciences, 14(10), 464–472.
Simmons, D. A., Rex, C. S., Palmer, L., Pandyarajan, V., Fedulov, V., Gall, C. M., & Lynch, G. (2009). Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington’s disease knockin mice. Proceedings of the National Academy of Sciences of the United States of America, 106(12), 4906–4911.
Smith, Y., & Villalba, R. (2008). Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Movement Disorders: Official Journal of the Movement Disorder Society, 23(Suppl 3), S534–S547.
Tong, X., Ao, Y., Faas, G. C., Nwaobi, S. E., Xu, J., Haustein, M. D., et al. (2014). Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington’s disease model mice. Nature Neuroscience, 17(5), 694–703.
Usdin, M. T., Shelbourne, P. F., Myers, R. M., & Madison, D. V. (1999). Impaired synaptic plasticity in mice carrying the Huntington’s disease mutation. Human Molecular Genetics, 8(5), 839–846.
van der Borght, K., & Brundin, P. (2007). Reduced expression of PSA-NCAM in the hippocampus and piriform cortex of the R6/1 and R6/2 mouse models of Huntington’s disease. Experimental Neurology, 204(1), 473–478.
Van Vugt, J., & Roos, R. (1999). Huntington’s disease: Options for controlling symptoms. CNS Drugs, 11(2), 105–123.
Weeks, R. (1997). Cortical control of movement in Huntington’s disease. A PET activation study. Brain, 120(9), 1569–1578.
Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., et al. (2002). Increased sensitivity to N-methyl-D-aspartate in a mouse model of Huntington’ s disease. Neuron, 33, 849–860.
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., et al. (2003). Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics, 35(1), 76–83.
Acknowledgments
We would like to thank Mr. Steve Walters, Mrs. Dawn Sadler, Mrs. Karen Evans, and Dr. Verina Waights at the Open University for their excellent technical assistance and Drs Tony Hannan and Anton van Dellen of Oxford University for their help in establishing our R6/1 colony. We would also like to thank Professor Michael Levine and Mr Ehud Gruen for providing D2 knock-out mouse brains. This work was funded by the Open University Research Development Committee and the Royal Society.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
None.
Rights and permissions
About this article
Cite this article
Dallérac, G.M., Cummings, D.M., Hirst, M.C. et al. Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington’s Disease. Neuromol Med 18, 146–153 (2016). https://doi.org/10.1007/s12017-016-8384-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-016-8384-z